Background
==========

*Plasmodium vivax*accounts worldwide for an estimated 70--80 million cases of malaria per year \[[@B1]\]. In some countries such as Brazil, *P. vivax*was responsible for approximately 79% of the 389,736 cases of the disease reported in 2001 \[[@B2]\].

Laboratory methods are important tools for the control of the disease progress. They can be useful for the individual diagnosis or for the patients\' follow-up after specific antimalaria treatment. Conventional light microscopy has been widely used for malaria diagnosis. However, outside areas where malaria is endemic, it is rarely performed. Also, this method is time consuming and requires trained personnel.

In attempts to overcome these problems several rapid diagnostic tests have been developed recently. These tests detect specific proteins such as HRP2, a histidine rich protein 2, or pLDH, lactate dehydrogenase, in unfractionated blood of patients with malaria. However, these assay do not differentiate *P. vivax*from *Plasmodium malariae*or *Plasmodium ovale*infections, and vary in their sensitivity and specificity (reviewed in reference \[[@B3]\]).

Molecular diagnosis by PCR is described as the most sensitive and specific method for *Plasmodium*detection. Genus- and species-specific primers have been used to amplify *Plasmodium*ssrRNA genes of the four human malaria parasites and to detect mixed infections \[[@B4]-[@B6]\]. However, this methodology is costly and requires trained personnel for its implementation.

Detection of antibodies by immunofluorescence or ELISA has been used for seroepidemiology of malaria. However, in the case of *P. vivax*, the difficulty of blood stage cultivation has been hindering the use of these methodologies. Production of recombinant proteins through the techniques of genetic engineering may provide sufficient *P. vivax*blood stage antigen(s) for the establishment of specific serological assays.

In the course of immuno-epidemiological studies using recombinant proteins based on the sequence of the Merozoite Surface protein-1 (MSP1) of *P. vivax,*we found that a recombinant protein representing the 19 kDa region of MSP1 (MSP1~19~) was highly immunogenic during natural infection in humans \[[@B7],[@B8]\]. This recombinant protein was recognized by antibodies of a large fraction of Brazilian individuals recently exposed to *P. vivax*\[[@B7]\]. This observation was subsequently confirmed in studies performed in Korea, where more than 90% of *P. vivax*-infected individuals displayed specific antibodies to *P. vivax*MSP1~19~\[[@B9]\]. Also important was the observation that the *P. vivax*MSP1~19~gene displays very limited allele polymorphism in different regions of the world that does not restrict recognition by human antibodies \[[@B10],[@B11]\]. Together, these results suggested that it could be possible to develop an ELISA using a single recombinant protein based on the *P. vivax*MSP1~19~. This relatively simple and inexpensive technique could be of great applicability for epidemiological studies, the screening of blood donors and the serological diagnosis of malaria caused by *P. vivax.*

In the present study three purified recombinant proteins produced in *E. coli*(GST-MSP1~19~, His~6~-MSP1~19~and His~6~-MSP1~19~-PADRE) and one in *Pichia pastoris*(yMSP1~19~-PADRE) were compared for their ability to be recognized by IgG antibodies of individuals with patent *P. vivax*infection. Serological evaluation was performed with serum samples collected from individuals living in areas endemic for malaria in the north of Brazil and compared to serum samples from individuals never exposed to *P. vivax*malaria.

Materials and methods
=====================

Study population
----------------

Sera from 430 individuals were used in this study, of which 200 were from patients with patent *P. vivax*malaria and 230 from persons not exposed to *P. vivax*malaria (negative controls). The blood samples from *P. vivax*patients were collected in the state of Pará, in the north of Brazil, in areas endemic for malaria: 103 from Belém, 21 from Marabá, 20 from Itaituba, 20 from Tailândia, 36 from Igarapé-Açu. Patent infection was documented by microscopic analysis of Giemsa-stained blood drops. These samples were obtained between January 1996 and July 1999 with informed consent of all individuals and kept at -20°C.

The 230 individuals non-exposed to *P. vivax*malaria included: (i) 49 donors to blood banks in the city of São Paulo, an area where malaria is not endemic (negative controls); (ii) 108 blood bank donors with unrelated infectious diseases, detected serologically; among them 21 with Chagas Disease, 21 with syphilis, 19 with HBV, 21 with HCV, 14 with HTLV and 12 with HIV; (iii) 10 individuals positive for antinuclear antibodies (ANA) and 10 for rheumatoid factors (RF); (iv) 53 individuals living in distinct areas in West Africa where malaria caused by *Plasmodium falciparum*is endemic: a) 26 adults without clear symptoms of malaria or other infectious disease from Senegal (n = 19) and Gambia (n = 7), b) seven children from Gambia during patent infection by *P. falciparum*, c) 20 malaria immune adults from Ghana. Aliquots of these samples were kindly supplied by Dr. Marcelo Urbano Ferreira (Universidade de São Paulo, São Paulo) and Dr. Silvia Di Santi (Superitendência de Controle de Endemias, SUCEN, São Paulo). Clinical and laboratory data were reported elsewhere \[[@B12]-[@B14]\].

Recombinant proteins
--------------------

The recombinant proteins used in the present study represent amino acids 1616--1704 of the MSP-1 (Belem strain) of *P. vivax*. These proteins were expressed in *E. coli*(GST-MSP1~19~, His~6~-MSP1~19~and His~6~-MSP1~19~-PADRE, ref. 15) or *Pichia pastoris*(yMSP1~19~-PADRE, ref. 16). The generation of the plasmids and expression/purification of the recombinant proteins produced in *E. coli*or *Pichia pastoris*were performed as described in references 15 and 16, respectively.

ELISA for detection of human antibodies
---------------------------------------

Human IgG antibodies against MSP1~19~were detected by ELISA as described \[[@B7]\]. ELISA plates were coated with 200 ng/well of each recombinant protein. The amount of recombinant protein gave the same OD~492~when we used an anti-MSP1~19~MAb \[[@B17]\]. Fifty μl of each solution were added to each of 96 well plates (High binding, Costar). After overnight incubation at room temperature (rt), the plates were washed with PBS-Tween (0.05%, v/v) and blocked with PBS-milk (5% w/v) for two hours at 37°C. Serum samples were diluted 1:100 in this same solution and 50 μl of each sample was added to each well in duplicate. After incubation for two hours at rt and washes with PBS-Tween, 50 μl a solution containing peroxidase-conjugated goat anti-human IgG (Fc specific) diluted 1:10,000 (Sigma) were added to each well. The enzymatic reaction was developed by the addition of 1 mg/ml of *o*-phenylenediamine (Sigma) diluted in phosphate-citrate buffer, pH 5.0, containing 0.03% (v/v) hydrogen peroxide, and was stopped by the addition of 50 μl of 4 N H~2~SO~4~. Plates were read at 492 nm (OD~492~) with an ELISA reader (SLT SPECTRA, SLT Labinstruments, Austria). The individual values of OD~492~obtained for the recombinant proteins of MSP1~19~were corrected by subtraction of the individual values of OD~492~obtained against glutathione S-transferase (GST).

Statistical analysis
--------------------

OD~492~from different samples were plotted using computer graphics software (GraphPad Prism, Version 3.0, San Diego, California). Cutoff values of each recombinant protein in ELISA were calculated as the mean OD~492~of sera from 49 blood donors plus five standard deviations (SD). The values for sensitivity and specificity were estimated as described \[[@B18]\] with microscopy used as the gold standard. The Kruskal-Wallis test was used to test the significance of differences between the group values. Differences between proportions were analyzed by a Chi-square test.

Results
=======

Reactivity of recombinant proteins expressed in distinct vectors with serum samples from individuals with patent *P. vivax*
---------------------------------------------------------------------------------------------------------------------------

Four recombinant proteins obtained as earlier described in references 15 and 16 (Table [1](#T1){ref-type="table"}) were used. SDS-PAGE analysis of each recombinant protein revealed a single band of the expected molecular weight after Coomassie blue \[[@B15],[@B16]\] or Silver staining (data not shown).

###### 

Recombinant proteins based on the MSP1~19~of *P. vivax*.

  **Recombinant protein**   **Vector**   **Microorganism**   **Molecular Weight (kDa)**   **Ref.**
  ------------------------- ------------ ------------------- ---------------------------- ----------
  GST-MSP1~19~              pGEX-3X      *E. coli*           36                           15
  His~6~-MSP1~19~           pET-14b      *E. coli*           18                           15
  His~6~-MSP1~19~-PADRE\*   pET-14b      *E. coli*           18                           15
  yMSP1~19~-PADRE\*         pPIC-9K      *Pichia pastoris*   18                           16

\* PADRE epitope is composed of amino acids AKFVAAWTLKAAA.

An IgG survey of the serum samples of individuals with patent *P. vivax*infection patients showed that the values of positivity were quite similar with the four recombinant antigens employed. Ninety to 93.5% of the 200 serum samples tested were positive for IgG with the recombinant proteins based on the MSP1~19~.

When we compared the OD~492~values from serum samples of *P. vivax*infected individuals, we observed that values obtained for the recombinant proteins His~6~-MSP1~19~and His~6~-MSP1~19~-PADRE were significantly higher than those obtained for GST-MSP1~19~(Fig. [1](#F1){ref-type="fig"}, P \< 0.01, Kruskal-Wallis test). On the other hand, no statistically significant difference was observed among values obtained by the comparison of the recombinant proteins His~6~-MSP1~19~, His~6~-MSP1~19~-PADRE and yMSP1~19~-PADRE, or GST-MSP1~19~and yMSP1~19~-PADRE (P \> 0.05, Kruskal-Wallis test).

![Distribution of OD~492~data for 200 sera from individuals with patent malaria infection caused by *P. vivax*. The symbols represent the reactivity of each serum sample tested in duplicate at 1:100 dilution against the indicated recombinant proteins. The horizontal line inside the drops for each recombinant protein represents the cut-off values (0.127, 0.170, 0.198 and 0.500 for GST-MSP1~19~, His~6~-MSP1~19~, His~6~-MSP1~19~-PADRE and yMSP1~19~-PADRE, respectively).](1475-2875-2-39-1){#F1}

Sera from the few individuals who tested negative towards all four recombinant proteins were also tested for the recognition of recombinant proteins representing the N-terminal region of *P. vivax*MSP1, MSP3α (C-terminal) or MSP3β(N and C-terminal and entire protein, references 19 and 20). All of them failed to recognize any of the recombinant protein tested (data not shown). However, we detected antibodies IgM anti-MSP1~19~in 90% (9/10) of these IgG negative individuals. If we consider the results of detection of antibodies IgG and IgM for MSP1~19~, the sensitivity of the assay was of 99.5%. These 10 individuals were primo-infected and therefore the presence of IgM but not IgG may reflect a delay in the immunoglobulin class switch.

From the 200 individuals that we evaluated, 111 were primo-infected. One hundred and one of them had specific IgG for the recombinant proteins that we tested. Only 10 were negative for IgG and, as mentioned above, 9 of them had specific IgM.

Evaluation of the specificity of the recombinant proteins tested with serum samples from individuals exposed to *P. falciparum*, from unrelated diseases, or healthy donors
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The specificity of the assay using recombinant *P. vivax*antigens was examined with 230 serum samples from individuals without previous history of *P. vivax*malaria, including individuals exposed to *P. falciparum*malaria, individuals with unrelated diseases or healthy individuals. Due to limitations on the volume of each sample available, sera from African individuals exposed to *P. falciparum*were tested only against recombinant protein His~6~-MSP1~19.~For the calculation of the specificity of the assay using the recombinant protein His~6~-MSP1~19~the results that was obtained did not include sera from African individuals. The specificity values determined with sera from healthy individuals and sera from individuals with other infectious diseases, were 98.3% (GST-MSP1~19~), 97.7% (His~6~-MSP1~19~and His~6~-MSP1~19~-PADRE) and 100% (yMSP1~19~-PADRE). In figure [2](#F2){ref-type="fig"}, we compared the OD~492~values from serum samples of *P. vivax*infected individuals, individuals exposed to *P. falciparum*and individuals with unrelated diseases.

![Distribution of the OD~492~data for sera from individuals with patent *P. vivax*malaria, from individuals exposed to *P. falciparum*, from individuals with unrelated diseases or healthy controls. The symbols represent the reactivity of each serum sample tested in duplicate at 1:100 dilution against the indicated recombinant proteins. The abbreviations are as follow: A) Pv= individuals with *P. vivax*malaria (n = 200), B) Pf= individuals from areas where *P. falciparum*malaria is endemic (n = 53), C) Cha = individuals with Chagas Disease (n = 21), D) Syp = individuals with syphilis (n = 21), E) HBV = individuals with hepatitis B (n = 19), F) HCV= individuals with hepatitis C (n = 21), G) HTLV = individuals with HTLV (n = 14), H) HIV= individuals with HIV (n = 12), I) ANA = individuals positive for antinuclear antibodies (n = 10), J) RF = individuals positive for rheumatoid factors (n = 10), L) Healthy = Healthy individuals (n = 49). Sera from African individuals exposed to *P. falciparum*were tested only against recombinant protein His~6~-MSP1~19.~The horizontal line inside the drops for each recombinant protein represents the cut-off values (0.127, 0.170, 0.198 and 0.500 for GST-MSP1~19~, His~6~-MSP1~19~, His~6~-MSP1~19~-PADRE and yMSP1~19~-PADRE, respectively).](1475-2875-2-39-2){#F2}

Discussion
==========

Due to the difficulties in cultivating blood stages of *P. vivax*, serological diagnosis of patent *P. vivax*malaria can best be accomplished with the use of recombinant proteins. In the present study, we compared for purified recombinant proteins produced in *E. coli*or in *Pichia pastoris*in their ability to be recognized by IgG antibodies of Brazilian individuals with patent *P. vivax*infection. Our study demonstrated that, for the Brazilian population, an ELISA using a single recombinant protein based on the *P. vivax*MSP1~19~kDa can serve as the basis for the development of a sensitive serological test that can be used for epidemiological studies, screening blood donors and diagnosis of *P. vivax*malaria.

So far, we do not have an estimate of the timing required after mosquito bite for the appearance of specific antibodies. To be accurate, this information should be obtained during experimental infection in primates. Nevertheless, we were able to determine that from the 111 primo-infected individuals that we evaluated, 101 (90.9%) had specific IgG to MSP1~19~. This information is important and suggests that IgG antibodies specific for MSP1~19~are suitable for testing individuals who are traveling or have traveled for the first time through malaria endemic areas. On the other hand, the persistence of the IgG antibodies specific for MSP1~19~is still a matter that has to be further evaluated. In previous studies we determined that the antibody titers decreased relatively rapidly after treatment \[[@B8]\]. However, studies are underway using these recently generated recombinant proteins.

An important observation from our study was the fact that sera from African individuals naturally exposed to *P. falciparum*failed to cross-react with the recombinant protein His~6~-MSP1~19~(Figure [2](#F2){ref-type="fig"}). As a control, 39 of these sera were also tested against a recombinant protein derived of the MSP-2 of *P. falciparum*. The percentage of responders was 69.2% (data not shown). The lack of cross-reactivity may have several implications and should be further evaluated in the light of the current knowledge that both MSP1~19~share similarities in their predicted tertiary structures \[[@B21]\]. For epidemiological studies, for the screening of blood donors and the serological diagnosis of *P. vivax*malaria, the lack of cross reactivity can be a major advantage. Nevertheless, the absence of cross-recognition of *P. vivax*MSP1~19~by antibodies from *P. falciparum*-exposed individuals has may also have immunological consequences at the level of acquired immunity and vaccine development in areas where both malarias are prevalent. Detailed studies will be required to determine whether sera from *P. vivax*infected individuals also fail to recognize recombinant proteins representing the *P. falciparum*MSP1~19~.

Recently, a direct sandwich ELISA to detect antibodies against the C-terminal region of MSP-1 was proposed as a potential diagnostic method for *Plasmodium vivax*exposed individuals from Korea \[[@B22]\]. This assay showed a high sensitivity (99.5%) indicating that recombinant proteins containing the C-terminal region of *P. vivax*MSP-1 may be used in individuals from different parts of the world.

It is also important to mention that it is very likely that serological detection of *P. vivax*malaria can be further improved by several distinct strategies. We are currently trying to improve the detection level by the combined use of other recombinant proteins based on the sequence of other blood stage antigens of *P. vivax*such as the *Plasmodium vivax*Merozoite Surface Proteins-3α and β, Apical Membrane Antigen-1 and the Duffy Binding Protein \[[@B19],[@B20],[@B23],[@B24]\]. Also, we are developing a chemiluminescent enzyme-linked immunosorbent assay that may greatly improve the sensitivity, eliminating the few false negative and false positive samples we had \[[@B25],[@B26]\].

Finally, our results support the notion that recombinant proteins based on the *P. vivax*MSP1~19~kDa can be useful for the development of a rapid immunochromatographic assay for field studies, small laboratories and blood banks (reviewed in references 3 and 27).

Conclusions
===========

Our study demonstrated that for the Brazilian population, an ELISA using a single recombinant protein based on the *P. vivax*MSP1~19~can serve as the basis for the development of a valuable serological assay for the detection of *P. vivax*malaria.
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